A first-of-its-kind clinical trial shows that therapeutic plasma exchange (TPE) combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as measured by multi-omic biomarkers. Results of the single-blind, placebo-controlled trial are published in Aging Cell.
This article was originally published on MedicalXpress.com